VBI Vaccines (NASDAQ:VBIV – Get Free Report) and Enveric Biosciences (NASDAQ:ENVB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.
Valuation and Earnings
This table compares VBI Vaccines and Enveric Biosciences’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VBI Vaccines | $8.68 million | 1.82 | -$92.84 million | ($11.68) | -0.05 |
| Enveric Biosciences | N/A | N/A | -$17.29 million | ($8.11) | -0.12 |
Enveric Biosciences has lower revenue, but higher earnings than VBI Vaccines. Enveric Biosciences is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VBI Vaccines | 0 | 0 | 0 | 0 | N/A |
| Enveric Biosciences | 0 | 0 | 1 | 0 | 3.00 |
Enveric Biosciences has a consensus price target of $10.00, suggesting a potential upside of 947.12%. Given Enveric Biosciences’ higher probable upside, analysts clearly believe Enveric Biosciences is more favorable than VBI Vaccines.
Risk & Volatility
VBI Vaccines has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Insider and Institutional Ownership
12.3% of VBI Vaccines shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 10.4% of VBI Vaccines shares are held by company insiders. Comparatively, 1.2% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares VBI Vaccines and Enveric Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VBI Vaccines | -1,069.29% | -234.77% | -47.11% |
| Enveric Biosciences | N/A | -349.01% | -187.74% |
Summary
Enveric Biosciences beats VBI Vaccines on 6 of the 11 factors compared between the two stocks.
About VBI Vaccines
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
About Enveric Biosciences
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
